FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166876116> ?p ?o ?g. }

• W2166876116 endingPage "52" @default.
• W2166876116 startingPage "45" @default.
• W2166876116 abstract "Abstract Objectives. We hypothesize that prostate cancer (PC) patients who achieve and maintain an undetectable prostate-specific antigen (UD-PSA) on androgen deprivation therapy (ADT) have a predominantly androgen-dependent cancer cell population sensitive to apoptosis that allows for a prolonged time off ADT. This study summarizes patient- and treatment-related factors associated with a prolonged time off ADT in patients electing intermittent androgen deprivation (IAD). Methods. Hormone-naïve patients with PC were treated with ADT using an antiandrogen and a luteinizing-hormone-releasing hormone-agonist. Of 255 consecutive patients, 216 (85%) achieved a UD-PSA (&lt;0.05 ng/ml). Ninety-three (43%) of 216 elected to stop ADT after maintaining a UD-PSA for a median of one year. Patients were followed off therapy and advised to restart ADT if the PSA level reached ≥5.0 ng/ml. Forty-one patients received finasteride as part of IAD induction and as maintenance off therapy; these patients are excluded from the current study and are the focus of another publication. The remaining 52 patients are assessable for response being either in the off-phase of IAD ≥1 year or having restarted IAD. Results. In the first IAD cycle, the median duration of the on-phase of IAD was 16 months (mean 19.0 months, range 3.6-71 months), and the median off-phase duration was 15.5 months (mean 24.1 months, range 3.2-87+ months). In 28 patients who maintained a UD-PSA for ≥1 year, their median off-phase duration was 29 months (mean 35.8 months, range 7.8-87+ months), with nine (32%) still off IAD after a median follow-up of 62 months. Significant (p &lt; 0.05) independent factors associated with prolonged off-phase duration by multivariate analysis included UD-PSA on ADT ≥1 year (p = 0.010), PSA-only recurrence after local therapy (p = 0.039), and reaching a testosterone level ≥150 ng/dl in ≥4 months off ADT (p = 0.041). After a median of 66 months of follow-up, only one (2%) patient developed androgen-independent PC. Conclusions. Hormone-naïve patients who achieve and maintain a UD-PSA for at least one year during ADT may initiate IAD and anticipate a prolonged off-phase duration. Attainment of a UD-PSA on ADT may serve as an in vivo sensitivity test of a patient's tumor cell population, and allow for better selection of those best suited for IAD." @default.
• W2166876116 created "2016-06-24" @default.
• W2166876116 creator A5014361897 @default.
• W2166876116 creator A5016962401 @default.
• W2166876116 creator A5051996540 @default.
• W2166876116 date "2000-02-01" @default.
• W2166876116 modified "2023-09-27" @default.
• W2166876116 title "Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time Off Therapy" @default.
• W2166876116 cites W116367892 @default.
• W2166876116 cites W1970881307 @default.
• W2166876116 cites W1979211241 @default.
• W2166876116 cites W1984562816 @default.
• W2166876116 cites W1990895663 @default.
• W2166876116 cites W1991178009 @default.
• W2166876116 cites W1994047807 @default.
• W2166876116 cites W2013354835 @default.
• W2166876116 cites W2014145760 @default.
• W2166876116 cites W2019378587 @default.
• W2166876116 cites W2026455376 @default.
• W2166876116 cites W2029676564 @default.
• W2166876116 cites W2037777722 @default.
• W2166876116 cites W2040997484 @default.
• W2166876116 cites W2048766864 @default.
• W2166876116 cites W2050743117 @default.
• W2166876116 cites W2074544671 @default.
• W2166876116 cites W2082333541 @default.
• W2166876116 cites W2092917417 @default.
• W2166876116 cites W2093109941 @default.
• W2166876116 cites W2126198426 @default.
• W2166876116 cites W2134661141 @default.
• W2166876116 cites W2178139012 @default.
• W2166876116 cites W2316095838 @default.
• W2166876116 cites W2484341741 @default.
• W2166876116 cites W4240322662 @default.
• W2166876116 cites W4252664364 @default.
• W2166876116 doi "https://doi.org/10.1634/theoncologist.5-1-45" @default.
• W2166876116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10706649" @default.
• W2166876116 hasPublicationYear "2000" @default.
• W2166876116 type Work @default.
• W2166876116 sameAs 2166876116 @default.
• W2166876116 citedByCount "62" @default.
• W2166876116 countsByYear W21668761162012 @default.
• W2166876116 countsByYear W21668761162013 @default.
• W2166876116 countsByYear W21668761162014 @default.
• W2166876116 countsByYear W21668761162015 @default.
• W2166876116 countsByYear W21668761162016 @default.
• W2166876116 countsByYear W21668761162017 @default.
• W2166876116 countsByYear W21668761162019 @default.
• W2166876116 countsByYear W21668761162022 @default.
• W2166876116 countsByYear W21668761162023 @default.
• W2166876116 crossrefType "journal-article" @default.
• W2166876116 hasAuthorship W2166876116A5014361897 @default.
• W2166876116 hasAuthorship W2166876116A5016962401 @default.
• W2166876116 hasAuthorship W2166876116A5051996540 @default.
• W2166876116 hasBestOaLocation W21668761161 @default.
• W2166876116 hasConcept C121608353 @default.
• W2166876116 hasConcept C126322002 @default.
• W2166876116 hasConcept C126894567 @default.
• W2166876116 hasConcept C141071460 @default.
• W2166876116 hasConcept C143998085 @default.
• W2166876116 hasConcept C2775874879 @default.
• W2166876116 hasConcept C2776235491 @default.
• W2166876116 hasConcept C2777899217 @default.
• W2166876116 hasConcept C2777911890 @default.
• W2166876116 hasConcept C2779322244 @default.
• W2166876116 hasConcept C2780192828 @default.
• W2166876116 hasConcept C2780275930 @default.
• W2166876116 hasConcept C2781406297 @default.
• W2166876116 hasConcept C2908647359 @default.
• W2166876116 hasConcept C530470458 @default.
• W2166876116 hasConcept C71315377 @default.
• W2166876116 hasConcept C71924100 @default.
• W2166876116 hasConcept C99454951 @default.
• W2166876116 hasConceptScore W2166876116C121608353 @default.
• W2166876116 hasConceptScore W2166876116C126322002 @default.
• W2166876116 hasConceptScore W2166876116C126894567 @default.
• W2166876116 hasConceptScore W2166876116C141071460 @default.
• W2166876116 hasConceptScore W2166876116C143998085 @default.
• W2166876116 hasConceptScore W2166876116C2775874879 @default.
• W2166876116 hasConceptScore W2166876116C2776235491 @default.
• W2166876116 hasConceptScore W2166876116C2777899217 @default.
• W2166876116 hasConceptScore W2166876116C2777911890 @default.
• W2166876116 hasConceptScore W2166876116C2779322244 @default.
• W2166876116 hasConceptScore W2166876116C2780192828 @default.
• W2166876116 hasConceptScore W2166876116C2780275930 @default.
• W2166876116 hasConceptScore W2166876116C2781406297 @default.
• W2166876116 hasConceptScore W2166876116C2908647359 @default.
• W2166876116 hasConceptScore W2166876116C530470458 @default.
• W2166876116 hasConceptScore W2166876116C71315377 @default.
• W2166876116 hasConceptScore W2166876116C71924100 @default.
• W2166876116 hasConceptScore W2166876116C99454951 @default.
• W2166876116 hasIssue "1" @default.
• W2166876116 hasLocation W21668761161 @default.
• W2166876116 hasLocation W21668761162 @default.
• W2166876116 hasOpenAccess W2166876116 @default.
• W2166876116 hasPrimaryLocation W21668761161 @default.
• W2166876116 hasRelatedWork W1982553076 @default.
• W2166876116 hasRelatedWork W1987790462 @default.

• next